Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1, a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate
With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review
Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate
With positive top-line pivotal trial results for its lead antibody drug conjugate SGN-35 for Hodgkin's lymphoma in hand, Seattle Genetics aims to file a BLA for the compound in the first half of 2011 and is hoping as well for priority review